FDA warns of reduced efficacy for oral birth control pill Tydemy

02 Aug 2023
www.pharmaceutical-technology.com
Drug ApprovalPhase 2Phase 3
FDA warns of reduced efficacy for oral birth control pill Tydemy
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
FDA warns of reduced efficacy for oral birth control pill Tydemy
Preview
Source: Pharmaceutical Technology
The US FDA recently approved Perrigo’s Opill (norgestrel), which does not require a prescription. Credit: Africa Studio / Shutterstock.
The US Food and Drug Administration (FDA) has issued a customer warning for Lupin Pharmaceuticals’ oral birth control pill Tydemy.
The FDA warns of reduced efficacy of Tydemy due to decreased levels of one of the inactive ingredients, ascorbic acid.
Recommended Reports
FDA warns of reduced efficacy for oral birth control pill Tydemy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Zoliflodacin in Uncomplicated Cervical And Urethral Gonorrhea GlobalData
FDA warns of reduced efficacy for oral birth control pill Tydemy
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Palonosetron Hydrochloride La in Chemotherapy Induced Nausea and Vomiting GlobalData
View allCompanies IntelligenceLupin LtdPerrigo CompanyLupin Pharmaceuticals IncNDCView all
The reduced efficacy is associated with two US lots, L200183 (expiry date January 2024; NDC Number 68180-904-71) and L201560 (expiry date September 2024; NDC Number 68180-904-73) distributed from 3 June 2022 to 31 May 2023.
On 28 July, Lupin issued a voluntary recall for the two lots following an out-of-specification (OOS) test reporting low levels of ascorbic acid and high levels of a known impurity in the L200183 lot.
Tydemy (drospirenone / ethinyl estradiol / levomefolate calcium) is a prescription oral contraceptive that prevents pregnancy by raising folate levels. As per Lupin’s 28 July press release, the reduction in ascorbic acid could impact Tydemy’s efficacy and could lead to an unexpected pregnancy.
The US FDA recently approved Perrigo’s Opill (norgestrel), which does not require a prescription, while many other contraceptives such as Tydemy need one.
Global sales of contraceptives are expected to reach £8.2bn by 2027, as per GlobalData forecasts. GlobalData has also identified an unmet need for hormone-free birth control pills. To that end, Singapore-based Navad Life Sciences is developing an oestrogen-free oral contraceptive, NA-0113, which is currently in a Phase II trial.
GlobalData is the parent company of Pharmaceutical Technology.
Other women’s health drug in Lupin’s pipeline includes Solosec (secnidazole), which is marketed for bacterial vaginosis.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.